Chemical reaction: Why AI drug discovery demands a new IP plan

With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

‘We created law’: G1/24 and the creation of the ‘diamond standard’

3 July 2025 The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips

Europe

UK govt sets sights on being AI drug discovery ‘world leader’

13 June 2025 Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.

More on this story

Europe

‘We created law’: G1/24 and the creation of the ‘diamond standard’

3 July 2025 The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips

Europe

UK govt sets sights on being AI drug discovery ‘world leader’

More on this story

Europe

‘We created law’: G1/24 and the creation of the ‘diamond standard’

3 July 2025 The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips

Europe

UK govt sets sights on being AI drug discovery ‘world leader’